Fate Therapeutics
FATE
$3.80
Share price
-1.81%
Change (1 day)
-37.40%
Change (1 year)
Categories
Fate Therapeutics (FATE) - Total debt
Total debt on the balance sheet as of December 2023 : $0.10 B
According to Fate Therapeutics 's latest financial reports the company's total debt is $0.10 B. A company’s total debt is the sum of all current and non-current debts.
Fate Therapeutics - Total debt on balance sheet (from 2012 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $0.10 B | -5.31% |
| 2022-12-31 | $0.10 B | -4.77% |
| 2021-12-31 | $0.11 B | 18.01% |
| 2020-12-31 | $97.29 M | 261.34% |
| 2019-12-31 | $26.92 M | 80.91% |
| 2018-12-31 | $14.88 M | 0.51% |
| 2017-12-31 | $14.8 M | 38.55% |
| 2016-12-31 | $10.68 M | -41.4% |
| 2015-12-31 | $18.23 M | -6.99% |
| 2014-12-31 | $19.6 M | 1032.1% |
| 2013-12-31 | $1.73 M | -52.85% |
| 2012-12-31 | $3.67 M | -24.1% |
| 2011-12-31 | $4.83 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Becton Dickinson BDX | $16.11 B | 15,459.81% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $1.39 B | 1,249.11% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | $2.22 B | 2,052.99% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $0.42 B | 313.77% | 🇺🇸 USA |
 Avidity Biosciences RNA | $9.85 M | -90.48% | 🇺🇸 USA |